Carbapenem-based Antibiotics Market

Carbapenem-based Antibiotics Market Size, Trend Analysis & Competition Tracking By Product Type (Meropenem, Ertapenem, Panipenem, Tebipenem), By Indication (Intra-abdominal Infections, Bacterial Meningitis, Skin and Skin Structure Infections, Acute Pelvic Infections) - Global Market Insights 2021 to 2031

Analysis of Carbapenem-based Antibiotics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Carbapenem-based Antibiotics Market to Register Strong Growth, on Back of Increasing Incidence of Hospital Acquired Pneumonia and Bacterial Infections

Incidence of bacterial infections is increasing rapidly across the world offering significant revenue generating opportunities for the carbapenem-based antibiotics market. Pneumonia acquired in hospital settings due to longer patient stays, is often difficult to treat and exists as the comorbidity to various chronic diseases such as cancer, organ transplant. etc. It also interferes with the disease treatment and may be fatal if not treated with broad-spectrum antibiotics such as carbapenem-based antibiotics.

Carbapenem based antibiotics market by Fact.MR

As per the Center for Disease Control (CDC), people admitted to hospital settings due to various reasons such as immunosuppressive treatment and inappropriately followed infection control protocol, suffer from hospital-acquired pneumonia (HAP). Along with HAP, incidence of various bacterial diseases is increasing rapidly, which in turn is expected to drive the growth of the carbapenem-based antibiotics market.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Surgery-Associated Bacterial Infection to Boost Demand for Carbapenem-Based Antibiotics

Some forms of chronic diseases often require open surgery as a treatment protocol. Before performing open surgery, carbapenem-based antibiotics are often administered as the prophylactic measure for the prevention of surgery-related bacterial infections.

The World Health Organization also emphasizes on infection control protocol i.e. prophylactic administration of the carbapenem-based antibiotics that can limit or eliminate the chances of surgery-associated bacterial infection. As per WHO, 30% of global disease burden is accruing to surgery related diseases pointing towards a heightened demand for prophylactic, carbapenem-based antibiotics.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Carbapenem-based Antibiotics Market Gains Traction, with Generic Alternatives to Ertapenem to be Lucrative Revenue Pockets

Ertapenem is one of the most widely used carbapenem-based antibiotics and its patent expired in November 2017. Various regional as well as global pharmaceutical companies are assessing feasibility for possible re- launch of generic version of ertapenem in various regions.

For instance, in June 2018, Aurobindo Pharma received FDA approval for generic Invanz injection. Invanz is Merck Sharp and Dohme Corp.’s joint carbapenem-based antibiotic product for the treatment of various bacterial infections. The launch of various generic version of carbapenem-based antibiotics such as ertapenem in regions such as North America and Europe is expected to offer substantial revenue generation opportunities.

Lower price of generic carbapenem-based antibiotics is expected to result in increased product adoption, thus compelling carbapenem-based antibiotic manufacturers to enhance geographical footprint in lower- and middle-income countries. Increasing supply-chain operations in regions such as North America, East Asia and Europe will further give impetus to high revenue generating carbapenem-based antibiotics markets.

Carbapenem based antibiotics market 01 by Fact.MR

Competitive Landscape

  • Pfizer Inc.
  • Merck Co. & Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.

are top players operating in the carbapenem-based antibiotics market. The top three players contributed more than 92% revenue share in the carbapenem-based antibiotics market in 2018.

Key players are prominently focusing on increasing their carbapenem-based antibiotics availability in different countries for the treatment of a large patient pool with bacterial infections.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Key Segments of Carbapenem-based Antibiotics Market

Fact.MR’s study on the carbapenem-based antibiotics therapy market offers information divided into four important segments - product, indication, sales channel, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.

Product Type
  • Meropenem
  • Ertapenem
  • Imipenem
  • Doripenem
  • Panipenem
  • Tebipenem
  • Intra-abdominal Infections
  • Urinary Tract Infections
  • Pneumonia
  • Bacterial Meningitis
  • Skin and Skin Structure Infections
  • Acute Pelvic Infections
  • Prophylaxis of Surgical Site Infection
  • Respiratory Tract Infections
  • Gynaecologic Infections
  • Endocarditis
  • Others
Sales Channel
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- FAQs -

In June 2018, Aurobindo Pharma received FDA approval for generic Invanz injection.

Meropenem,Ertapenem,Doripenem,Panipenem,Tebipenem are the product types of Carbapenem-based Antibiotics Market.

Carbapenem-based Antibiotics Market

Schedule a Call

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic.

By clicking "Accept All", you consent to our use of cookies. Privacy Policy